Status: Recruiting

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).

Participants needed: 28

Trial details

Phase: Phase 3Age: 2-18Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Aug 7, 2026Locations: 9

Eligibility criteria

Signed informed consent by parent(s)/legal guardian(s) for the pediatric patient... [+7]

Participation in any other investigational drug trial or use of other investigat... [+37]

Status: Not yet recruiting

FXS6837 for the Treatment for IgAN Patients（Longterm Study）

This is a multicenter, open-label study to evaluate the long-term safety and efficacy of FXS6837 capsules in primary IgAN patients. About 60 IgAN patients who had received and completed FXS6837-IIb-201 study treatment will be enrolled to take FXS6837 capsules orally according to protocol for 2 years.

Participants needed: 60

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Updated: Aug 6, 2026Locations: 1

Eligibility criteria

Have completed the study treatment in FXS6837-IIb-201, and are evaluated by the...

Known or suspected by investigators to have immunodeficiency diseases or heredit...